Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 2/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253612 | 0.92 | KDM4E (0.53) | KDM4EITGB2ICAM1ITGALLMNA | |
| SCHEMBL10725093 | 0.85 | LMNA (0.53) | KDM4EITGB2ICAM1ITGALLMNA | |
| SCHEMBL8488850 | 0.83 | KDM4E (0.91) | KDM4ETDP1MTNR1AHTTCTNNB1 | |
| SCHEMBL8488847 | 0.83 | KDM4E (0.91) | KDM4ETDP1MTNR1AHTTCTNNB1 | |
| SCHEMBL161792 | 0.83 | GSK3B (0.54) | KDM4ELMNAMEN1THRBBLM | |
| SCHEMBL29706697 | 0.83 | GSK3B (0.54) | KDM4ELMNAMEN1THRBBLM | |
| SCHEMBL6851157 | 0.81 | TDP1 (0.46) | KDM4EITGB2ICAM1ITGALLMNA | |
| SCHEMBL3026099 | 0.81 | KDM4E (0.54) | KDM4EITGB2ICAM1ITGALLMNA | |
| SCHEMBL2676229 | 0.81 | KDM4E (0.54) | KDM4EITGB2ICAM1ITGALLMNA | |
| SCHEMBL29236578 | 0.79 | KDM4E (0.41) | KDM4ELMNAMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358169-B1 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | EP | claimed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | claimed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | claimed |
| US-12528793-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2026-01-20 | — | — | US | disclosed |
| EP-4642765-A1 | COMPOUNDS AFFECTING KRAS | Universitat de Barcelona (ES) | 2025-11-05 | — | — | EP | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| CN-115380029-B | Compounds for the treatment of tuberculosis | 南洋理工大学 | 2025-06-17 | — | — | CN | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| EP-0158211-B1 | 1,4-DIHYDROPYRIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USES AS MEDICAMENTS | LABORATORIOS DELAGRANGE S.A. (ES) | 1992-08-26 | — | — | EP | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0458823-A1 | A PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES. | BOEHRINGER MANNHEIM ITALIA (IT) | 1991-12-04 | — | — | EP | disclosed |
| WO-1990009376-A1 | A PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-08-23 | — | — | WO | disclosed |
| EP-0383320-A1 | A process for preparation of enantiomerically pure polysubstituted 1,4-dihydropyridines | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-08-22 | — | — | EP | disclosed |
| CN-1032786-A | N-acyl amino acid derivative and uses thereof | BANYU PHARMA CO LTD (JP) | 1989-05-10 | — | — | CN | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4722931-A | MUSCLE RELAXANTS | LABORATORIOS DELAGRANGE (ES) | 1988-02-02 | — | — | US | disclosed |
| EP-0158211-A2 | 1,4-Dihydropyridin derivatives, process for their preparation and their uses as medicaments | LABORATORIOS DELAGRANGE S.A. (ES) | 1985-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | KDM4E 4044/4885ITGB2 3529/4885ICAM1 3053/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | KDM4E 4044/4885ITGB2 3529/4885ICAM1 3053/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | KDM4E 2774/4885ITGB2 4751/4885ICAM1 4699/4885 |
| US-12528793-B2 | Compounds for treating tuberculosis | TPMT, UQCRB, ARG1 | KDM4E 814/4885ITGB2 1344/4885ICAM1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.